AU2005243469A1 - Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug - Google Patents

Description

au-f il COMMONWEALTH OF AUSTRALIA PATENTS ACT 1990 IN THE MATTER of a Patent Application by Boehringer Ingelheim Pharma GmbH & Co. KG VERIFICATION OF TRANSLATION Patent Application No.: PCT/EP2005/005079 I, JANE ROBERTA MANN, B.A., of Frank B. Dehn & Co., 59 St Aldates, Oxford OXI 1ST, am the translator of the documents attached and I state that the following is a true translation to the best of my knowledge and belief of the specification as published of International Patent Application No. PCT/EP2005/005079 of Boehringer Ingelheim Pharma GmbH & Co. KG. Signature of translator Dated: 18th September 2006 WO 2005/111005 1 PCT/EP2005/005079 87405pct NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG 5 The present invention relates to enantiomerically pure compounds of general formula I O O OH H H R HN N R Me Me X R3 OH R4 wherein the groups R', R 2 , R 3 , R 4 and X may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical 10 compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints. Background to the invention Betamimetics (f-adrenergic substances) are known from the prior art. For example 15 reference may be made in this respect to the disclosure of US 4,460,581, which proposes betamimetics for the treatment of a range of diseases. For drug treatment of diseases it is often desirable to prepare medicaments with a longer duration of activity. As a rule, this ensures that the concentration of the active substance in 20 the body needed to achieve the therapeutic effect is guaranteed for a longer period without the need to re-administer the drug at frequent intervals. Moreover, giving an active substance at longer time intervals contributes to the well-being of the patient to a high degree. 25 It is particularly desirable to prepare a pharmaceutical composition which can be used therapeutically by administration once a day (single dose). The use of a drug once a day has the advantage that the patient can become accustomed relatively quickly to regularly taking the drug at certain times of the day.

WO 2005/111005 2 PCT/EP2005/005079 The aim of the present invention is to provide betamimetics which on the one hand confer a therapeutic benefit in the treatment of respiratory complaints and are also characterised by a longer duration of activity and can thus be used to prepare pharmaceutical compositions with a longer duration of activity. A particular aim of the invention is to 5 prepare betamimetics which, by virtue of their long-lasting effect, can be used to prepare a drug for administration once a day for treating respiratory complaints. A further objective of the invention, apart from those mentioned above, is to prepare betamimetics which are not only exceptionally potent but are also characterised by a high degree of selectivity with respect to the p 2 -adrenoceptor. 10 A further aim of the present invention is to prepare betamimetics which by virtue of their physicochemical properties are particularly suitable for preparing pharmaceutical formulations for use by inhalation. The present invention sets out in particular to prepare betamimetics which, in addition to the above-mentioned properties, are particularly 15 suitable for preparing inhalable powders and suspension aerosols. Detailed description of the invention Surprisingly it has been found that these objectives are achieved with compounds of general formula 1. 20 The present invention relates to enantiomerically pure compounds of general formula 1 O OH H H R HN N R Me Me | X R3 OH 4 wherein R1 denotes hydrogen, CI-C 4 -alkyl, Ci-C 4 -alkoxy or halogen; 25 R 2 denotes hydrogen, CI-C 4 -alkyl, C 1

-C

4 -alkoxy or halogen; R 3 denotes hydrogen, CI-C 4 -alkyl, Ci-C 4 -alkoxy, halogen, OH, -0-Ci-C 4 -alkylene-COOH or -0-Ci-C 4 -alkylene-COO-Ci-C 4 -alkyl; R 4 denotes hydrogen, Ci-C 4 -alkyl, Ci-C 4 -alkoxy or halogen; WO 2005/111005 3 PCT/EP2005/005079 X~ denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, 5 benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof. Preferred are enantiomerically pure compounds of general formula 1, wherein 10 R' denotes hydrogen or halogen; R2 denotes hydrogen or halogen; R3 denotes hydrogen, CI-C 4 -alkoxy or halogen; R 4 denotes hydrogen or halogen; X~ denotes an anion with a single negative charge, preferably an anion with a 15 single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates 20 thereof. Preferred are enantiomerically pure compounds of general formula 1, wherein RI denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine; R 2 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine; 25 R 3 denotes hydrogen, methoxy, ethoxy, fluorine or chlorine, preferably hydrogen, methoxy, ethoxy or fluorine; R 4 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine; X- an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, 30 phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof. 35 WO 2005/111005 4 PCT/EP2005/005079 Preferred are enantiomerically pure compounds of general formula 1, wherein R' Denotes hydrogen or fluorine; R2 denotes hydrogen; R 3 denotes methoxy, ethoxy or fluorine; 5 R 4 denotes hydrogen; X- denotes an anion with a single negative charge selected from among chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate and succinate; optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates 10 thereof. Of equal importance according to the invention are also enantiomerically pure compounds of general formula 1, wherein R' Denotes hydrogen; 15 R 2 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine; R 3 denotes hydrogen; R 4 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine; X- denotes an anion with a single negative charge selected from among chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, 20 salicylate, trifluoroacetate, fumarate, tartrate and succinate; optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof. Also preferred are enantiomerically pure compounds of general formula 1, wherein 25 X~ denotes an anion with a single negative charge selected from among chloride, methanesulphonate, maleate, acetate, citrate, salicylate, trifluoroacetate, fumarate and succinate, preferably chloride, maleate, salicylate, fumarate and succinate, particularly preferably chloride; and R', R 2 , R 3 and R 4 may have the meanings given above, optionally in the form of the 30 tautomers, mixtures of the tautomers, hydrates or solvates thereof. Also particularly preferred are compounds of general formula I which are selected from among - 6-hydroxy-8- { (R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl-ethylamino] 35 ethyl }-4H-benzo[ 1,4]oxazin-3-one hydrochloride; WO 2005/111005 5 PCT/EP2005/005079 - 8- {(R)-2-[2-(2,4-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy-ethyl} -6 hydroxy-4H-benzo[1,4]oxazin-3-one hydrochloride; - 8- {(R)-2-[2-(3,5-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy-ethyl} -6 hydroxy-4H-benzo[1,4]oxazin-3 -one hydrochloride; 5 - 8- {(R)-2-[2-(4-ethoxy-phenyl)-1,1 -dimethyl-ethylamino]-1 -hydroxy-ethyl}-6 hydroxy-4H-benzo[ 1,4]oxazin-3-one hydrochloride; - 8- {(R)-2-[2-(4-fluoro-phenyl)- 1, I-dimethyl-ethylamino]-1 -hydroxy-ethyl}-6 hydroxy-4H-benzo[1,4]oxazin-3-one hydrochloride; - 6-hydroxy-8- {(R)- 1 -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl-ethylamino] 10 ethyl} -4H-benzo[ l,4,]oxazin-3-one maleate; - 6-hydroxy-8- {(R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl-ethylamino] ethyl }-4H-benzo[1,4,]oxazin-3-one salicylate; - 6-hydroxy-8- {(R)- 1 -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl-ethylamino] ethyl}-4H-benzo[l,4,]oxazin-3-one succinate; 15 - 6-hydroxy-8- {(R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl-ethylamino] ethyl} -4H-benzo[ I,4,]oxazin-3-one fumarate; - 8-{(R)-2-[2-(2,4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6 hydroxy-4H-benzo[1,4]oxazin-3-one maleate; - 8- {(R)-2-[2-(2,4-di fluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy-ethyl }-6 20 hydroxy-4H-benzo[1,4]oxazin-3-one salicylate; - 8- {(R)-2-[2-(2,4-di fluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy-ethyl }-6 hydroxy-4H-benzo[ 1,4]oxazin-3-one succinate; - 8- {(R)-2- [2-(2,4-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]-1 -hydroxy-ethyl }-6 hydroxy-4H-benzo[ 1,4]oxazin-3-one fumarate; 25 - 8- {(R)-2-[2-(3,5-di fluoro-phenyl)- I, I -dimethyl-ethylamino]-I -hydroxy-ethyl } -6 hydroxy-4H-benzo[1,4]oxazin-3-one maleate; - 8-{(R)-2-[2-(3,5-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6 hydroxy-4H-benzo[ 1,4]oxazin-3-one salicylate; - 8- {(R)-2-[2-(3,5-di fluoro-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl } -6 30 hydroxy-4H-benzo[1,4]oxazin-3-one succinate; - 8- {(R)-2-[2-(3,5-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} -6 hydroxy-4H-benzo[1,4]oxazin-3-one fumarate; - 8- {(R)-2-[2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} -6 hydroxy-4H-benzo[ 1,4]oxazin-3-one maleate; WO 2005/111005 6 PCT/EP2005/005079 - 8-{(R)-2-[2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6 hydroxy-4H-benzo[1,4]oxazin-3-one salicylate; - 8- {(R)-2- [2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylamino]- 1 -hydroxy-ethyl} -6 hydroxy-4H-benzo[I,4]oxazin-3-one succinate; 5 - 8-{(R)-2-[2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamino]-I -hydroxy-ethyl}-6 hydroxy-4H-benzo[1,4]oxazin-3-one fumarate; - 8- {(R)-2-[2-(4-fluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy-ethyl}-6 hydroxy-4H-benzo[1,4]oxazin-3-one maleate; - 8-{(R)-2-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylamino]-I -hydroxy-ethyl}-6 10 hydroxy-4H-benzo[1,4]oxazin-3-one salicylate; - 8- {(R)-2-[2-(4-fluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy-ethyl} -6 hydroxy-4H-benzo[I1,4]oxazin-3-one succinate and - 8- {(R)-2-[2-(4-fluoro-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} -6 hydroxy-4H-benzo[I,4]oxazin-3-one fumarate, 15 optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof. Also particularly preferred are enantiomerically pure compounds of general formula 1, wherein R', R 2 , R 3 , R 4 and X have the meanings given above, in crystalline form, 20 optionally in the form of their crystalline tautomers, crystalline hydrates or crystalline solvates. Particularly preferred are enantiomerically pure, crystalline compounds of general formula I wherein R', R 2 , R 3 , R 4 and X- have the meanings given above, optionally in the form of their crystalline tautomers, crystalline hydrates or crystalline solvates, which are further characterised in that they are crystalline compounds which are present in only a 25 single crystal modification. By the expression "a single crystal modification" are meant crystalline compounds of formula I which are not a mixture of any polymorphic crystal modifications that may exist. 30 The compounds of formula 1 according to the invention are characterised by their versatility of use in the therapeutic field. Particular mention should be made according to the invention of those possible applications for which the compounds according to the invention of formula I are preferably used on account of their pharmaceutical efficacy as betamimetics. 35 WO 2005/111005 7 PCT/EP2005/005079 In another aspect the present invention therefore relates to the above-mentioned enantiomerically pure compounds of formula 1 as pharmaceutical compositions. The present invention also relates to the use of the above-mentioned compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of respiratory 5 complaints. The present invention preferably relates to the use of the above-mentioned compounds of general formula I for preparing a pharmaceutical composition for the treatment of respiratory complaints which are selected from among obstructive pulmonary diseases of various origins, pulmonary emphysema of various origins, restrictive pulmonary diseases, 10 interstitial pulmonary diseases, cystic fibrosis, bronchitis of various origins, bronchiectasis, ARDS (adult respiratory distress syndrome) and all forms of pulmonary oedema. It is preferable to use compounds of general formula I for preparing a pharmaceutical 15 composition for the treatment of obstructive pulmonary diseases which are selected from among COPD (chronic obstructive pulmonary disease), bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis, while it is particularly preferable according to the invention to use them for preparing a pharmaceutical composition for the treatment of bronchial asthma. 20 It is also preferable to use compounds of general formula I for preparing a pharmaceutical composition for the treatment of pulmonary emphysemas that have their origin in COPD (chronic obstructive pulmonary disease) or al -proteinase inhibitor deficiency. 25 It is also preferable to use compounds of general formula I for preparing a pharmaceutical composition for the treatment of restrictive pulmonary diseases, which are selected from among allergic alveolitis, restrictive pulmonary diseases triggered by work-related noxious substances, such as asbestosis or silicosis, and restriction caused by lung tumours, such as for example lymphangiosis carcinomatosa, bronchoalveolar carcinoma and lymphomas. 30 It is also preferable to use compounds of general formula I for preparing a pharmaceutical composition for the treatment of interstitial pulmonary diseases which are selected from among pneumonia caused by infections, such as for example infection by viruses, bacteria, fungi, protozoa, helminths or other pathogens, pneumonitis caused by various factors, such 35 as for example aspiration and left heart insufficiency, radiation-induced pneumonitis or WO 2005/111005 8 PCT/EP2005/005079 fibrosis, collagenoses, such as for example lupus erythematodes, systemic sclerodermy or sarcoidosis, granulomatoses, such as for example Boeck's disease, idiopathic interstitial pneumonia or idiopathic pulmonary fibrosis (IPF). 5 It is also preferable to use compounds of general formula I for preparing a pharmaceutical composition for the treatment of cystic fibrosis or mucoviscidosis. It is also preferable to use compounds of general formula I for preparing a pharmaceutical composition for the treatment of bronchitis, such as for example bronchitis caused by 10 bacterial or viral infection, allergic bronchitis and toxic bronchitis. It is also preferable to use compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of bronchiectasis. 15 It is also preferable to use compounds of general formula I for preparing a pharmaceutical composition for the treatment of ARDS (adult respiratory distress syndrome). It is also preferable to use compounds of general formula 1 for preparing a pharmaceutical composition for the treatment of pulmonary oedemas, for example toxic pulmonary 20 oedema after aspiration or inhalation of toxic substances and foreign substances. Particularly preferably, the present invention relates to the use of the compounds of formula I for preparing a pharmaceutical composition for the treatment of asthma or COPD. Also of particular importance is the above-mentioned use of compounds of formula 25 1 for preparing a pharmaceutical composition for once-a-day treatment of inflammatory and obstructive respiratory complaints, particularly for the once-a-day treatment of asthma or COPD. Moreover the present invention relates to a method of treating the above-mentioned 30 diseases, characterised in that one or more of the above-mentioned compounds of general formula I are administered in therapeutically effective amounts. The present invention preferably relates to methods of treating asthma or COPD, characterised in that one or more of the above-mentioned compounds of general formula I are administered once a day in therapeutically effective amounts. 35 WO 2005/111005 9 PCT/EP2005/005079 Unless otherwise stated, the alkyl groups are straight-chained or branched alkyl groups having 1 to 4 carbon atoms. The following are mentioned by way of example: methyl, ethyl, propyl or butyl. In some cases the abbreviations Me, Et, Prop or Bu are used to denote the groups methyl, ethyl, propyl or butyl. Unless otherwise stated, the definitions 5 propyl and butyl include all the possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and iso-propyl, butyl includes iso-butyl, sec.butyl and tert.-butyl, etc. Unless otherwise stated, the alkylene groups are branched and unbranched double-bonded 10 alkyl bridges with 1 to 4 carbon atoms. Examples include: methylene, ethylene, n propylene or n-butylene. Unless otherwise stated, the term alkyloxy groups (or -0-alkyl groups) denotes branched and unbranched alkyl groups having I to 4 carbon atoms which are linked via an oxygen 15 atom. Examples of these include: methyloxy, ethyloxy, propyloxy or butyloxy. The abbreviations MeO-, EtO-, PropO- or BuO- are used in some cases to denote the groups methyloxy, ethyloxy, propyloxy or butyloxy. Unless otherwise stated, the definitions propyloxy and butyloxy include all possible isomeric forms of the groups in question. Thus, for example, propyloxy includes n-propyloxy and iso-propyloxy, butyloxy includes 20 iso-butyloxy, sec.butyloxy and tert.-butyloxy, etc. In some cases, within the scope of the present invention, the term alkoxy is used instead of the term alkyloxy. Accordingly, the terms methoxy, ethoxy, propoxy or butoxy may also be used to denote the groups methyloxy, ethyloxy, propyloxy or butyloxy. 25 Within the scope of the present invention halogen denotes fluorine, chlorine, bromine or iodine. Unless otherwise stated, fluorine, chlorine and bromine are the preferred halogens. The term enantiomerically pure within the scope of the present invention describes compounds of formula I which are present with an enantiomeric purity of at least 85%ee, 30 preferably at least 90%ee, particularly preferably > 95%ee. The term ee (enantiomeric excess) is known in the art and describes the optical purity of chiral compounds.

WO 2005/111005 10 PCT/EP2005/005079 The preparation of the compounds according to the invention may be carried out according to the method outlined in Diagram 1. O. 0 OH HN Me HN L L OPG OPG OPG 2 3 4 R

H

2 N R2 Me Me 3 OH H R HN HN N R Me Me R OPG OPG R4 0 7 O O OH H H R HN NR Me Me X I ~ R3 OH R4 5 Diagram 1: In the compounds of formulae 2 to 5 and 7 specified in Diagram I the group OPG denotes a hydroxyl function protected by a protective group (PG). With regard to the choice of suitable protective groups for the hydroxyl group reference is hereby made to the prior art as laid out for example in Protective Groups in Organic Synthesis, T.W. Greene and 10 P.G.M. Wuts, John Wiley & Sons Inc, Third Edition, 1999. Preferably OPG denotes a group which is selected from among -0-Ci-C 4 -alkyl, -O-benzyl or -O-CO-C,-C 4 -alkyl, preferably -0-methyl, -0-benzyl or -0-acetyl, particularly preferably -0-methyl or -0 benzyl, particularly preferably -O-benzyl. 15 WO 2005/111005 11 PCT/EP2005/005079 In the compounds of formulae 3 and 4 specified in Diagram I the group L denotes a leaving group. Preferably L denotes a leaving group which is selected from among chlorine, bromine, iodine, methanesulphonate, trifluoromethanesulphonate and p toluenesulphonate, preferably chlorine or bromine, particularly preferably chlorine. 1 2 5 In the compounds of formulae 6 and 7 specified in Diagram 1 the groups R , R2, R 3 and R 4 may have the meanings given above. Starting from 8-acetyl-6-benzyloxy-4H-benzo[1,4]oxazin-3-one (2) the compounds of general formula 3 are prepared in the manner known in the art. The compound of formula 10 3 is then enantioselectively converted, in the presence of a chiral transition metal catalyst, into the chiral alcohol of general formula 4, which is then reacted under suitable conditions to form the chiral oxiran of formula 5. Methods of carrying out the enantioselective synthesis of oxirans are known in the art (cf. for example Hamada et al., Org. Letters 2002, 4, 4373-4376). 15 By reacting the oxirans 5 with the amines of formula 6 the compounds of formula 7 are obtained, which can be converted into the salts of formula 1 after the protective group (PG) has been cleaved. In view of their central importance as intermediate products in the synthesis of the 20 compounds of formula I according to the invention, in another aspect the present invention relates to the compounds of formula 5 per se 0 O HN OPG 5 wherein OPG denotes a hydroxyl function protected by a protective group PG, preferably a 25 group which is selected from -O-Ci-C 4 -alkyl, -O-benzyl or -0-CO-Ci-C 4 -alkyl, preferably -0-methyl, -O-benzyl or -0-acetyl, particularly preferably -0-methyl or -O-benzyl, particularly preferably -O-benzyl. In another aspect the present invention relates to the use of a compound of formula 5 , 30 wherein OPG may have the meanings given above, as starting compound for preparing a WO 2005/111005 12 PCT/EP2005/005079 1 2 3 4 compound of formula 1, wherein the groups R1, R , R , R and X may have the meanings given above. In another aspect the present invention relates to the use of a compound of formula 5 , wherein OPG may have the meanings given above, for preparing a compound of formula 1, wherein the groups R , R 2, R 3, R4 and X may have the meanings given 5 above. In the light of their central importance as intermediate products in the synthesis of the compounds of formula I according to the invention, in another aspect the present invention relates to the compounds of formula 7 per se 01 0 OH H R Y 1 2 HN N R Me Me 1 R3 10 OPG R4 wherein OPG denotes a hydroxyl function protected by a protective group PG, preferably a group which is selected from -O-Ci-C 4 -alkyl, -O-benzyl or -O-CO-Ci-C 4 -alkyl, preferably -0-methyl, -O-benzyl or -0-acetyl, particularly preferably 15 -0-methyl or -0-benzyl, particularly preferably -0-benzyl, and wherein the groups R', R 2 , R 3 and R 4 may have the meanings given above. In another aspect the present invention relates to the use of a compound of formula 7, wherein OPG, R', R 2 , R 3 and R 4 may have the meanings given above, as an intermediate 20 product in the preparation of a compound of formula, wherein the groups R', R 2 , R 3 , R 4 and X~ may have the meanings given above. In another aspect the present invention relates to the use of a compound of formula 7, wherein OPG, R', R 2 , R 3 and R 4 may have the I 2 meanings given above, for preparing a compound of formula 1, wherein the groups R', R2

R

3 , R 4 and X~ may have the meanings given above. 25 The enantiomerically pure compounds of formula I may optionally also be obtained by the method illustrated in Diagram 2.

WO 2005/111005 13 PCT/EP2005/005079 OH H R O OH H R 22 HN N R HN N R Me Me Me Me R 3R' OPG R4 OH R4 71' 0+ 0 H1 O O OH HH R HN N R

H-X

Me Me X I~ R 3 OH R Diagram 2: The compound of formula 7 which may be obtained according to Diagram 1 may then 5 optionally be converted first of all into the free bases of formula ', while the groups R', 2 3 4 R , R and R 4 may have the meanings given above. The free bases of formula ' are converted by reaction with a suitable acid H-X into the compounds of formula 1, which may be obtained in crystalline form by precipitation in a suitable solvent, for example in an alcohol, preferably in an alcohol selected from isopropanol, ethanol or methanol, 10 optionally mixtures thereof, such as for example isopropanol/methanol mixtures. In the light of their central importance as possible intermediate products in the synthesis of the compounds of formula 1 according to the invention, in another aspect the present invention relates to the compounds of formula 1' per se 15 0 0 OH R HN N R Me Me OH R14 wherein the groups R1, R 2 , R 3 and R 4 may have the meanings given above.

WO 2005/111005 14 PCT/EP2005/005079 In another aspect the present invention relates to the use of a compound of formula ' 1 2 3 4 wherein R , R , R and R may have the meanings given above, as an intermediate product in the preparation of a compound of formula 1, wherein the groups R', R2, R', R4 and X may have the meanings given above. 5 In another aspect the present invention relates to the use of a compound of formula 1' , wherein R , R 2, R3 and R 4 may have the meanings given above, for preparing a compound I 2 3 4 of formula 1, wherein the groups R', R , R , R and X may have the meanings given above. 10 The reactions carried out are described in an exemplary capacity in the following experimental section of this patent application. The examples of synthesis described below serve to illustrate new compounds according to the invention. However, they are intended purely as examples of methods as an illustration of the invention without restricting it to the subject matter described below by way of example. 15 Example 1: 6-hydroxy-8- {(R)- 1 -hydroxy-2-[2-(4-methoxy-phenyl)- 1, 1 -dimethyl ethylaminol-ethyl }-4H-benzor l,4]oxazin-3-one hydrochloride O OH H HN N OXe x HCI HOMe

OH

WO 2005/111005 15 PCT/EP2005/005079 a) 1-(5-benzyloxy-2-hydroxy-3-nitro-phenyl)-ethanone 18 mL fuming nitric acid are added dropwise to a solution of 81.5 g (0.34 mol) 1-(5 benzyloxy-2-hydroxy-phenyl)-ethanone in 700 mL acetic acid while cooling with the ice bath, so that the temperature does not exceed 20'C. Then the reaction mixture is stirred for 5 two hours at ambient temperature, poured onto ice water and filtered. The product is recrystallised from isopropanol, suction filtered and washed with isopropanol and diisopropylether. Yield: 69.6 g (72%); mass spectroscopy [M+H] = 288. b) 1-(3-amino-5-benzyloxy-2-hydroxy-phenyl)-ethanone 10 69.5 g (242 mmol) l-(5-benzyloxy-2-hydroxy-3-nitro-phenyl)-ethanone are dissolved in 1.4 L methanol and hydrogenated in the presence of 14 g rhodium on charcoal (10%) as catalyst at 3 bar and ambient temperature. Then the catalyst is filtered off and the filtrate is evaporated down. The residue is reacted further without additional purification. Yield: 60.0 g (96%), Rf value = 0.45 (dichloromethane on silica gel). 15 c) 8-acetyl-6-benzyloxy-4H-benzor 1,41oxazin-3-one 21.0 mL (258 mmol) chloroacetyl chloride are added dropwise to 60.0 g (233 mmol) 1-(3 amino-5-benzyloxy-2-hydroxy-phenyl)-ethanone and 70.0 g (506 mmol) potassium carbonate while being cooled with the ice bath. Then the mixture is stirred overnight at 20 ambient temperature and then for 6 hours at reflux temperature. The hot reaction mixture is filtered, then evaporated down to approx. 400 mL and combined with ice water. The precipitate obtained is suction filtered, dried and purified by chromatography on a short silica gel column (dichloromethane:methanol = 99:1). The fractions containing the product are evaporated down, suspended in isopropanol/diisopropylether, suction filtered and 25 washed with diisopropylether. Yield: 34.6 g (50%); mass spectroscopy [M+H]* = 298. d) 6-benzyloxy-8-(2-chloro-acetyl)-4H-benzo[1,4]oxazin-3-one 13.8 g (46.0 mmol) 8-acetyl-6-benzyloxy-4H-benzo[1,4]oxazin-3-one and 35.3 g (101.5 mmol) benzyltrimethylammonium-dichloriodate are stirred in 250 mL dichloroethane, 84 30 mL glacial acetic acid and 14 mL water for 5 hours at 65'C. After cooling to ambient temperature the mixture is combined with 5% sodium hydrogen sulphite solution and stirred for 30 minutes. The precipitated solid is suction filtered, washed with water and diethyl ether and dried. Yield: 13.2 g (86%); mass spectroscopy [M+H]+ = 330/32. 35 e) 6-benzyloxy-8-((R)-2-chloro-1-hydroxy-ethyl)-4H-benzo[1,41-oxazin-3-one WO 2005/111005 16 PCT/EP2005/005079 The method is carried out analogously to a process described in the literature (Org. Lett. 2002, 4, 4373-4376). 8 mL of a mixture of formic acid and triethylamine (molar ratio = 5:2) are added dropwise at -1 5*C to 13.15 g (39.6 mmol) 6-benzyloxy-8-(2-chloro-acetyl)-4H-benzo[1,4]oxazin-3 5 one and 25.5 mg (0.04 mmol) Cp*RhCl[(S,S)-TsDPEN] (Cp* = pentamethylcyclopentadienyl and TsDPEN = (I S,2S)-N-p-toluenesulphonyl- 1,2 diphenylethylenediamine) in 40 mL dimethylformamide. The mixture is stirred for 5 hours at this temperature, then 25 mg catalyst are added and the mixture is stirred overnight at -l 5'C. The reaction mixture is combined with ice water and filtered. The filter residue is 10 dissolved in dichloromethane, dried with sodium sulphate and freed from the solvent. The residue is chromatographed (dichloromethane/methanol gradient) and the product recrystallised from diethyl ether/diisopropylether. Yield: 10.08 g (76%); Rf value = 0.28 (dichloromethane:methanol = 50:1 on silica gel). 15 f) 6-benzyloxy-8-(R)-oxiranyl-4H-benzor,4]oxazin-3-one 10.06 g (30.1 mmol) 6-benzyloxy-8-((R)-2-chloro- I -hydroxy-ethyl)-4H-benzo[ 1,4] oxazin-3-one are dissolved in 200 mL dimethylformamide. The solution is combined at 0*C with 40 mL of a 2 molar sodium hydroxide solution and stirred at this temperature for 4 hours. The reaction mixture is poured onto ice water, stirred for 15 minutes and then 20 filtered. The solid is washed with water and dried. Yield: 8.60 g (96%); mass spectroscopy [M+H]+ = 298. g) 6-benyloxy-8- {(R)- I -hydroxy-2-r2-(4-methoxy-phenyl)- 1,1 -dimethyl-ethylaminol ethyl 1-4H-benzor 1,4,loxazin-3-one 25 5.25 g (17.7 mmol) 6-benzyloxy-8-(R)-oxiranyl-4H-benzo[ 1,4]oxazin-3-one and 6.30 g (35.1 mmol) 2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamine are combined with 21 mL isopropanol and stirred for 30 minutes at 135'C under microwave radiation in a closed reaction vessel. The solvent is distilled off and the residue is chromatographed (aluminium oxide; ethyl acetate/methanol gradient). The product thus obtained is further purified by 30 recrystallisation from a diethyl ether/diisopropylether mixture. Yield: 5.33 g (63%); mass spectroscopy [M+H]+ = 477. h) 6-hydroxy-8-{(R)-1-hydroxy-2-[2-(4-methoxy-phenyl)-1.1-dimethyl-ethylaminol ethyl I -4H-benzor I,4,loxazin-3-one-hydrochloride WO 2005/111005 17 PCT/EP2005/005079 A suspension of 5.33 g (11.2 mmol) 6-benyloxy-8-{(R)-l -hydroxy-2-[2-(4-methoxy phenyl)- 1,1 -dimethyl-ethylamino]-ethyl } -4H-benzo[ 1,4,]oxazin-3-one in 120 mL methanol is combined with 0.8 g palladium on charcoal (10%), heated to 50'C and hydrogenated at 3 bar hydrogen pressure. Then the catalyst is suction filtered and the filtrate is evaporated 5 down. The residue is dissolved in 20 mL isopropanol and 2.5 mL of 5 molar hydrochloric acid in isopropanol is added. The product is precipitated with 200 mL diethyl ether, suction filtered and dried. Yield: 4.50 g (95%, hydrochloride); mass spectroscopy [M+H]* = 387. The following compounds of formula I are obtained analogously by reacting the 10 compound 6-benzyloxy-8-(R)-oxiranyl-4H-benzo [I ,4]oxazin-3 -one (Example 1, Step 0 with the corresponding amine. Example 2: 8-{(R)-2-r2-(2,4-difluoro-phenyl)-1,1-dimethyl-ethylaminol-l-hydroxy ethyl }-6-hydroxy-4H-benzor 1,4]oxazin-3-one-hydrochloride O OH F HN N x HCI Me Me 15 OH mass spectroscopy [M+H] = 393. Example 3: 8- (R)-2-[2-(3,5-difluoro-phenyl)- 1,1 -dimethyl-ethylaminol- I -hydroxy ethyl }-6-hydroxy-4H-benzo[ 1,4loxazin-3-one-hydrochloride O O OH H HN N F x HCI MeXMe)? 20 OH F mass spectroscopy [M+H]+ = 393. Example 4: 8- {(R)-2-[2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylaminol- I -hydroxy-ethyl }-6 hydroxy-4H-benzor 1,4]oxazin-3-one-hydrochloride WO 2005/111005 18 PCT/EP2005/005079 O O OH H HN N x HCI M MMe' _ 0 Me OH mass spectroscopy [M+H]* = 401. Example 5: 8- {R)-2-[2-(4-fluoro-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl }-6 5 hydroxy-4H-benzo[ 1,4]oxazin-3-one hydrochloride O O OHH HN e N x HCI Me Me OH mass spectroscopy [M+H]* = 375. If in some cases the compounds of formula 1 according to the method of synthesis 10 described by way of example hereinbefore do not lead to uniform crystal modifications, it may be useful to crystallise the salts of formula 1 obtained from suitable solvents. In addition, other salts may be obtained from the foregoing Examples by using methods known per se in the art. 15 In the next section some exemplary methods of preparing uniform salts of the compounds of formula 1 which are particularly suitable for the preparation of inhalable formulations will be described. Example 6: 6-hydroxy-8- {(R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl 20 ethylaminol-ethyl I -4H-benzo[ I,4,oxazin-3 -one maleate 250 mg (0.65 mmol) 6-hydroxy-8-{(R)-I-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl ethylamino]-ethyl }-4H-benzo[ 1,4,]oxazin-3-one are combined with enough ethanol to make the solid dissolve completely. Then 75 mg (0.65 mmol) maleic acid and a crystallisation aid are added. The mixture is cooled with ice and the precipitated solid is 25 filtered off and washed with ethanol and diethyl ether. In the salt the acid and the ethanolamine are present in the ratio 1:1. Yield: 254 mg (78%); mass spectroscopy [M+H]* = 387; melting point = 215*C.

WO 2005/111005 19 PCT/EP2005/005079 The highly crystalline product was further investigated by X-ray powder diffraction . The X-ray powder diagram was recorded as follows. The X-ray powder diagram was recorded within the scope of the present invention using a Bruker D8 Advanced with an LSD (= location sensitive detector) (CuKa - radiation, k = 5 1.5418 A, 30 kV, 40 mA). For the highly crystalline compound the following characteristic values dhkI [A], which give the lattice plane distances measured in A, were determined, inter alia: d= 21.68 A; 8.62 A; 5.92 A; 5.01 A; 4.59 A; 4.36 A; 3.64 A and 3.52 A. 10 Example 7: 6-hydroxy-8- (R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl ethylamino]-ethyl I -4H-benzo[ 1,4,]oxazin-3-one salicylate 250 mg (0.65 mmol) 6-hydroxy-8- {(R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl ethylamino]-ethyl}-4H-benzo[l,4,]oxazin-3-one are dissolved in a little ethanol and 15 combined with 90 mg (0.65 mmol) salicylic acid. After the addition of a crystallisation aid the mixture is left to stand overnight, during which time a solid is precipitated. Diethyl ether is added and the mixture is filtered after 30 minutes. The white solid thus obtained is washed with diethyl ether and dried. Yield: 295 mg (87%); mass spectroscopy [M+H] = 387; melting point = 215'C. 20 The highly crystalline product was further investigated by X-ray powder diffraction . The X-ray powder diagram was recorded as follows. The X-ray powder diagram was recorded within the scope of the present invention using a Bruker D8 Advanced with an LSD (= location sensitive detector) (CuKa - radiation, k = 25 1.5418 A, 30 kV, 40 mA). For the highly crystalline compound the following characteristic values dhkI [A], which give the lattice plane distances measured in A, were determined, inter alia: d= 9.06 A; 8.36 A; 8.02 A; 6.84 A; 6.73 A; 4.48 A; 4.35 A and 4.27 A. 30 Example 8: 6-hydroxy-8- {(R)- 1 -hydroxy-2-r2-(4-methoxy-phenyl)- 1, 1 -dimethyl ethylaminol-ethyl I -4H-benzor I,4,1oxazin-3-one succinate 500 mg (1.2 mmol) 6-hydroxy-8- {(R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1, 1 -dimethyl ethylamino]-ethyl} -4H-benzo[ 1,4,]oxazin-3 -one hydrochloride are combined with ethyl 35 acetate and extracted with aqueous potassium carbonate solution, the organic phase is dried WO 2005/111005 20 PCT/EP2005/005079 with sodium sulphate and freed from the solvent. The residue is dissolved in a little ethanol and combined with 140 mg (1.2 mmol) succinic acid. After 2 hours the precipitated solid is suction filtered and washed with cold ethanol and diethyl ether. In the salt the ethanolamine and acid are present in a ratio of I to 0.5. 5 Yield: 468 mg (85%); mass spectroscopy [M+H]*= 387; melting point = 1 15 0 C. The highly crystalline product was further investigated by X-ray powder diffraction . The X-ray powder diagram was recorded as follows. The X-ray powder diagram was recorded within the scope of the present invention using a 10 Bruker D8 Advanced with an LSD (= location sensitive detector) (CuKa - radiation, k = 1.5418 A, 30 kV, 40 mA). For the highly crystalline compound the following characteristic values dhkj [A], which give the lattice plane distances measured in A, were determined, inter alia: 15 d= 14.35 A; 8.49 A; 7.37 A; 7.25 A; 5.47 A; 4.78 A; 4.14 A and 3.59 A. Example 9: 6-hydroxy-8- { (R)- 1 -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl ethylaminol-ethyl }-4H-benzor 1,4,1oxazin-3-one-fumarate 300 mg (0.71 mmol) 6-hydroxy-8- {(R)- I -hydroxy-2-[2-(4-methoxy-phenyl)- 1,1 -dimethyl 20 ethylamino] -ethyl} -4H-benzo[ 1,4,]oxazin-3-one hydrochloride are combined with ethyl acetate and extracted with aqueous potassium carbonate solution. The organic phase is dried with sodium sulphate and freed from the solvent. The residue is dissolved in ethanol with the addition of a few drops of water. 82 mg (0.71 mmol) fumaric acid and seed crystals are added and the mixture is left to stand overnight. The white solid is suction 25 filtered, washed with diethyl ether and ethanol and dried. In the salt the ethanolamine and the acid are present in a ratio of I to 0.5. Yield: 208 mg (63%); mass spectroscopy [M+H]+ = 387; melting point = 130*C. The highly crystalline product was further investigated by X-ray powder diffraction. The 30 X-ray powder diagram was recorded as follows. The X-ray powder diagram was recorded within the scope of the present invention using a Bruker D8 Advanced with an LSD (= location sensitive detector) (CuKa - radiation, X = 1.5418 A, 30 kV, 40 mA).

WO 2005/111005 21 PCT/EP2005/005079 For the highly crystalline compound the following characteristic values dhkl [A], which give the lattice plane distances measured in A, were determined, inter alia: d= 14.23 A; 5.44 A; 4.76 A; 4.57 A; 4.26 A; 4.12 A; 3.57 A and 3.48 A. 5 Example 10: 6-hydroxy-8- { I -hydroxy-2-r2-(4-methoxy-phenyl)- 1,1 -dimethyl ethylaminol-ethyl I -4H-benzo [1,4,1oxazin-3-one (free base) Analogously to the preceding methods 500 mg (1.2 mmol) 6-hydroxy-8-{(R)-1-hydroxy-2 [2-(4-methoxy-phenyl)- 1,1 -dimethyl-ethylamino]-ethyl }-4H-benzo[ 1,4,]oxazin-3-one hydrochloride are first of all combined with ethyl acetate. The organic phase is extracted 10 with aqueous potassium carbonate solution, dried with sodium sulphate and freed from the solvent. The free base thus obtained is dissolved in acetonitrile with the addition of a few drops of water. The precipitated solid is suction filtered, washed and dried. Yield: 168 mg (37%); mass spectroscopy [M+H]* = 387; melting point = 128*C. 15 The highly crystalline product was further investigated by X-ray powder diffraction. The X-ray powder diagram was recorded as follows. The X-ray powder diagram was recorded within the scope of the present invention using a Bruker D8 Advanced with an LSD (= location sensitive detector) (CuKa - radiation, X = 1.5418 A, 30 kV, 40 mA). 20 For the highly crystalline compound the following characteristic values dhkI [A], which give the lattice plane distances measured in A, were determined, inter alia: d= 14.96 A; 9.63 A; 7.05 A; 5.57 A; 5.28 A; 5.05 A; 4.63 A and 3.73 A. 25 Example 11: 6-hydroxy-8-{(R)-1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl ethylaminol-ethyl }-4H-benzo[ 1,4,1oxazin-3-one-hydrochloride 300 mg (0.71 mmol) 6-hydroxy-8- {(R)- 1 -hydroxy-2-[2-(4-methoxy-phenyl)- 1, 1 -dimethyl ethylamino]-ethyl }-4H-benzo[ 1,4,]oxazin-3-one hydrochloride are dissolved in 4 mL isopropanol by heating. The solution is cooled to ambient temperature and then placed in 30 an ice bath for 15 minutes. The precipitated solid is suction filtered and dried. Yield: 180 mg (60%); mass spectroscopy [M+H] = 387; melting point = 21 1 0 C. The highly crystalline product was further investigated by X-ray powder diffraction. The X-ray powder diagram was recorded as follows.

WO 2005/111005 22 PCT/EP2005/005079 The X-ray powder diagram was recorded within the scope of the present invention using a Bruker D8 Advanced with an LSD (= location sensitive detector) (CuKa - radiation, X = 1.5418 A, 30 kV, 40 mA). 5 For the highly crystalline compound the following characteristic values dhkl [A], which give the lattice plane distances measured in A, were determined, inter alia: d= 5.92 A; 5.81 A; 5.51 A; 5.10 A; 4.65 A; 4.50 A; 4.15 A and 4.00 A. Using the method described in Examples 6 to l Ithe following compounds may be 10 obtained analogously: Example 12: 8- {(R)-2-[2-(2,4-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]-1 -hydroxy ethyl }-6-hydroxy-4H-benzo[1,4]oxazin-3-one maleate; 15 Example 13: 8- {(R)-2-[2-(2,4-difluoro-phenyl)- 1, 1 -dimethyl-ethylamino]-I -hydroxy ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one salicylate; Example 14: 8- {(R)-2-[2-(2,4-difluoro-phenyl)- ],I -dimethyl-ethylamino]-I -hydroxy ethyl }-6-hydroxy-4H -benzo[1,4]oxazin-3-one succinate; 20 Example 15: 8- { (R)-2-[2-(2,4-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]-1 -hydroxy ethyl} -6-hydroxy-4H-benzo[ 1,4]oxazin-3 -one fumarate; Example 16: 8- {(R)-2-[2-(3,5-di fluoro-phenyl)- 1,1 -dimethyl-ethyl amino]- I -hydroxy 25 ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one maleate; Example 17: 8- {(R)-2-[2-(3,5-difluoro-phenyl)- ],I -dimethyl-ethylamino]-I -hydroxy ethyl} -6-hydroxy-4H-benzo[ 1,4]oxazin-3-one salicylate; 30 Example 18: 8- {(R)-2-[2-(3,5-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one succinate; Example 19: 8- {(R)-2-[2-(3,5-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]-I -hydroxy ethyl }-6-hydroxy-4H-benzo[1,4]oxazin-3-one fumarate; 35 WO 2005/111005 23 PCT/EP2005/005079 Example 20: 8- {(R)-2-[2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} 6-hydroxy-4H-benzo[1,4]oxazin-3-one maleate; Example 21: 8- {(R)-2-[2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} 5 6-hydroxy-4H-benzo[1,4]oxazin-3-one salicylate; Example 22: 8- {(R)-2-[2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} 6-hydroxy-4H-benzo[1,4]oxazin-3-one succinate; 10 Example 23: 8- {(R)-2-[2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylamino]- 1 -hydroxy-ethyl} 6-hydroxy-4H-benzo[1,4]oxazin-3-one fumarate; Example 24: 8-{(R)-2-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylamino]-l -hydroxy-ethyl} 6-hydroxy-4H-benzo[ l,4]oxazin-3-one maleate; 15 Example 25: 8-{(R)-2-[2-(4-fluoro-phenyl)-1,1 -dimethyl-ethylamino]- I-hydroxy-ethyl} 6-hydroxy-4H-benzo[1,4]oxazin-3-one salicylate; Example 26: 8- {(R)-2-[2-(4-fluoro-phenyl)- 1,1 -dimethyl-ethylamino]-1 -hydroxy-ethyl} 20 6-hydroxy-4H-benzo[I,4]oxazin-3-one succinate; Example 27: 8- {(R)-2-[2-(4-fluoro-phenyl)- 1,1 -dimethyl-ethylamino]- 1 -hydroxy-ethyl) 6-hydroxy-4H-benzo[1,4]oxazin-3-one fumarate; 25 Example 28: 8- {(R)-2-[2-(2,4-difluoro-phenyl)- 1, 1 -dimethyl-ethylamino]- I -hydroxy ethyl) -6-hydroxy-4H-benzo[ 1,4]oxazin-3-one (free base); Example 29: 8- {(R)-2-[2-(3,5-difluoro-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one (free base); 30 Example 30: 8- {(R)-2-[2-(4-ethoxy-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} 6-hydroxy-4H-benzo[ 1,4]oxazin-3-one (free base) or Example 31: 8- {(R)-2-[2-(4-fluoro-phenyl)- 1,1 -dimethyl-ethylamino]- I -hydroxy-ethyl} 35 6-hydroxy-4H-benzo[ 1,4]oxazin-3-one (free base).

WO 2005/111005 24 PCT/EP2005/005079 The compounds of general formula I may be used on their own or in conjunction with other active substances of formula 1 according to the invention. If desired the compounds 5 of general formula 1 may also be used in conjunction with other pharmacologically active substances. Preferably the present invention also relates to drug combinations which contain in addition to one or more, preferably one compound of formula 1, as an additional active substance one or more compounds selected from the categories of the anticholinergics, 10 PDEIV inhibitors, steroids, LTD4-antagonists and EGFR inhibitors. Anticholinergics are preferably used, while compounds selected from bromides and chlorides of the cations tiotropium, oxitropium, flutropium, ipratropium, glycopyrronium and trospium are of particular interest. Of particular importance is tiotropium bromide, 15 preferably in the form of crystalline tiotropium bromide monohydrate, which is known from WO 02/30928. If tiotropium bromide is used in the drug combinations according to the invention in anhydrous form, it is preferable to use anhydrous crystalline tiotropium bromide, which is known from WO 03/000265. 20 In another preferred embodiment of the present invention the anticholinergic used is the compound 0 N 0 Br HO S S optionally in the form of the enantiomers thereof. 25 The following compounds are optionally also used as anticholinergics in combination with the compounds of formula 1: - tropenol 2,2-diphenylpropionate methobromide, - scopine 2,2- diphenylpropionate methobromide, - scopine 2-fluoro-2,2-diphenylacetate methobromide, WO 2005/111005 25 PCT/EP2005/005079 - tropenol 2-fluoro-2,2-diphenylacetate methobromide, - tropenol 3,3',4,4'-tetrafluorobenzilate methobromide, - scopine 3,3',4,4'-tetrafluorobenzilate methobromide, - tropenol 4,4'-difluorobenzilate methobromide, 5 - scopine 4,4'-difluorobenzilate methobromide, - tropenol 3,3'-difluorobenzilate methobromide, - scopine 3,3'-difluorobenzilate methobromide, - tropenol 9-hydroxy- fluorene-9-carboxylate methobromide; - tropenol 9-fluoro-fluorene-9-carboxylate methobromide; 10 - scopine 9-hydroxy-fluorene-9-carboxylate methobromide; - scopine 9-fluoro-fluorene-9-carboxylate methobromide; - tropenol 9-methyl-fluorene-9-carboxylate methobromide; - scopine 9-methyl-fluorene-9-carboxylate methobromide; - cyclopropyltropine benzilate methobromide, 15 - cyclopropyltropine 2,2-diphenylpropionate methobromide; - cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide; - cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide ; - cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide; - cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide; 20 - methyl cyclopropyltropine 4,4'-difluorobenzilate methobromide. - tropenol 9-hydroxy-xanthene-9-carboxyl ate methobromide; - scopine 9-hydroxy-xanthene-9-carboxylate methobromide; - tropenol 9-methyl-xanthene-9-carboxylate methobromide; - scopine 9-methyl-xanthene-9-carboxylate methobromide; 25 - tropenol 9-ethyl-xanthene-9-carboxylate methobromide; - tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide; or - scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide. If PDE IV inhibitors are used in combination with one or more compounds of general 30 formula ., these are preferably selected from among Enprofyllin, Theophyllin, Roflumilast, Ariflo (Cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12 281 (GW-842470), N-(3,5-dichloro- 1 -oxo-pyridin-4-yl)-4-di fluoromethoxy-3 cyclopropylmethoxybenzamide, NCS-613, Pumafentine, (-)p-[(4aR*, 10bS*)-9-ethoxy 1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[s][1,6]naphthyridin-6-yl]-N,N 35 diisopropylbenzamide, (R)-(+)- I -(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4- WO 2005/111005 26 PCT/EP2005/005079 methoxyphenyl]-2-pyrrolidone, 3-(cyclopentyloxy-4-methoxyphenyl)- I -(4-N'-[N-2-cyano S-methyl-isothioureido]benzyl)-2-pyrrolidone, cis[4-cyano-4-(3-cyclopentyloxy-4 methoxyphenyl)cyclohexane- 1 -carboxylic acid], 2-carbomethoxy-4-cyano-4-(3 cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-one, cis[4-cyano-4-(3 5 cyclopropylmethoxy-4-di fluoromethoxyphenyl)cyclohexan-1-ol], (R)-(+)-ethyl[4-(3 cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, (S)-(-)-ethyl[4-(3 cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, CDP840, Bay-198004, D 4418, PD-168787, T-440, T-2585, Arofyllin, Atizoram, V-11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2 10 thienyl)-9H-pyrazolo[3,4-c]-I,2,4-triazolo[4,3-a]pyridine and 9-cyclopentyl-5,6-dihydro-7 ethyl-3 -(tert-butyl)-9H-pyrazolo[3 ,4-c]- 1,2,4-triazolo[4,3-a]pyridine, optionally in the form of their racemates, enantiomers or diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates and/or hydrates. By acid addition salts with pharmacologically acceptable acids are meant for example salts selected 15 from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate. 20 If steroids are used in combination with one or more compounds of general formula L they are preferably selected from among prednisolone, prednisone, butixocortpropionate, RPR 106541, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, ST-126, dexamethasone, (S)-fluoromethyl 6a,9aX 25 difluoro- I 7ct-[(2-furanylcarbonyl)oxy]- 11p -hydroxy- I 6ax-methyl-3-oxo-androsta- 1,4 diene- I 7p-carbothionate, and (S)-(2-oxo-tetrahydro-furan-3 S-yl)6a,9X-di fluoro- 110p hydroxy- I 6ax-methyl-3-oxo- I 7ax-propionyloxy-androsta- 1,4-diene- I 7p-carbothionate, optionally in the form of their racemates, enantiomers or diastereomers and optionally in the form of their salts and derivatives, the solvates and/or hydrates thereof. Any reference 30 to steroids includes a reference to any salts or derivatives, hydrates or solvates thereof that may exist. Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as for example sodium or potassium salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogenphosphates, palmitates, pivalates or furoates. 35 WO 2005/111005 27 PCT/EP2005/005079 If LTD4-antagonists are used in combination with one or more compounds of general formula 1, these are preferably selected from among montelukast, l -(((R)-(3-(2-(6.7 difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2- hydroxy-2 propyl)phenyl)thio)methylcyclopropane-acetic acid, 1 -(((1 (R)-3(3-(2-(2,3 5 dichlorothieno[3 ,2-b)pyridine-5-yI)-(E)-ethenyl)phenyl)-3 -(2-(1 -hydroxy- 1 methylethyl)phenyl)propyl)thio)methyl)cyclopropanacetic acid, pranlukast, zafirlukast, [2 [[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707 and L-733321, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the 10 form of their pharmacologically acceptable acid addition salts as well as optionally in the form of their salts and derivatives, the solvates and/or hydrates thereof. By acid addition salts with pharmacologically acceptable acids which the LTD4-antagonists may be capable of forming are meant, for example, salts selected from among hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, 15 hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p toluenesulphonate, preferably hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate. By salts or derivatives which the LTD4-antagonists ,may be capable of forming are meant, for example: alkali 20 metal salts, such as for example sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates. If EGFR inhibitors are used in combination with one or more compounds of general 25 formula 1, they are preferably selected from among 4-[(3-chloro-4-fluorophenyl)amino]-6 {[4-(morpholin-4-yl)- I -oxo-2-buten- I -yl]amino} -7-cyclopropylmethoxy-quinazoline, 4 [(3-chloro-4-fluoro-phenyl)amino]-6- { [4-((R)-6-methyl-2-oxo-morpholin-4-yl)- I -oxo-2 buten-1-yl] amino} -7-[(S)-(tetrahydrofuran-3 -yl)oxy]-quinazoline, 4-[(3-chloro-4-fluoro phenyl)amino]-6- [2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy] -7-methoxy-quinazoline, 30 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino)-1-oxo 2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino] 6.7-bis-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4 (morpholin-4-yl)- 1 -oxo-2-buten- 1 -yl]amino } -7-[(tetrahydrofuran-2-yl)methoxy] quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)- 1 35 oxo-2-buten-1-yl]amino} -quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4- WO 2005/111005 28 PCT/EP2005/005079 methanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4 fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4 fluoro-phenyl)amino]-6-{ 1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6- { -[2-(2-oxopyrrolidin-1-yl)ethyl] 5 piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-acetyl piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-methyl piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-( 1 methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl phenyl)amino]-6- {I -[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy} -7-methoxy 10 quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(2-methoxyethyl)carbonyl] piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4 (N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4 [(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1 yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4 15 methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7 methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6 (trans-4- {N-[(morpholin-4-yl)carbonyl]-N-methyl-amino } -cyclohexan- I -yloxy)-7 20 methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro 4-fluoro-phenyl)amino]-6-(I -methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline and 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy quinazoline, optionally in the form of their racemates, enantiomers or diastereomers, 25 optionally in the form of their pharmacologically acceptable acid addition salts, the solvates and/or hydrates thereof. By acid addition salts with pharmacologically acceptable acids which the above-mentioned EGFR inhibitors might be capable of forming are meant, for example, salts selected from 30 among hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate. 35 WO 2005/111005 29 PCT/EP2005/005079 Suitable preparations for administering the compounds of formula j. include tablets, capsules, suppositories, solutions, powders, etc. The proportion of pharmaceutically active compound or compounds should be in the range from 0.05 to 90 % by weight, preferably 5 0.1 to 50 % by weight of the total composition. Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, 10 cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers. Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, 15 arabic gum, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets. 20 Syrups or elixirs containing the active substances or combinations of active substances according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of 25 fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates. Solutions are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if 30 water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.

WO 2005/111005 30 PCT/EP2005/005079 Capsules containing the compounds of formula I according to the invention may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules. 5 Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof. Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut 10 or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and 15 sodium lauryl sulphate). For oral administration the tablets may, of course, contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the 20 like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above. 25 When the compounds of formula I are used, as is particularly preferred according to the invention, for the treatment of respiratory complaints, it is particularly preferable to use preparations or pharmaceutical formulations that can be administered by inhalation. Suitable formulations for inhalation include inhalable powders, propellant-driven metered -dose aerosols or propellant-free inhalable solutions. Within the scope of the present 30 invention the term propellant-free inhalable solutions also includes concentrates or sterile ready-to-use inhalable solutions. The compounds of formula 1 which are particularly preferably used in crystalline form according to the invention are preferably used for preparing inhalable powders. The inhalable powders which may be used according to the invention may contain the WO 2005/111005 31 PCT/EP2005/005079 crystalline compounds of formula 1 either on their own or in admixture with suitable physiologically acceptable excipients. If the active substances are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare 5 these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in 10 the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred. Within the scope of the inhalable powders according to the invention the excipients have a maximum average particle size of up to 250 pm, preferably between 10 and 150 pm, most preferably between 15 and 80 pm. In some cases it may seem appropriate to add finer 15 excipient fractions with an average particle size of I to 9 pm to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to prepare the inhalable powders according to the invention, micronised active substance, preferably with an average particle size of 0.5 to 10 pm, more preferably from I to 5 pm, is added to the excipient mixture. Processes for producing the 20 inhalable powders according to the invention by grinding and micronising and finally mixing the ingredients together are known from the prior art. The inhalable powders according to the invention may be administered using inhalers known from the prior art. The inhalation aerosols containing propellant gas according to the invention may contain 25 dissolved in the propellant gas or in dispersed form. The propellant gases which may be used to prepare the inhalation aerosols are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The above-mentioned propellant gases may be used on their 30 own or in admixture. Particularly preferred propellant gases are halogenated alkane derivatives selected from TGI34a and TG227 and mixtures thereof.

WO 2005/111005 32 PCT/EP2005/005079 The propellant-driven inhalation aerosols may also contain other ingredients such as co -solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. All these ingredients are known in the art. 5 The propellant-driven inhalation aerosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs = metered dose inhalers). The dosage of the compounds according to the invention is naturally highly dependent on 10 the method of administration and the complaint which is being treated. When administered by inhalation the compounds of the formula are characterised by a high potency even at doses in the pg range. The compounds of the formula may also be used effectively above the pg range. The dosage may then be in the milligram range, for example. 15 In another aspect the present invention relates to the above-mentioned pharmaceutical formulations, characterised in that they contain a compound of formula 1, as such, particularly preferably the above-mentioned pharmaceutical formulations for use by inhalation. 20 The following formulation examples illustrate the present invention without restricting its scope: Examples of pharmaceutical formulations 25 A) Tablets per tablet active substance 100 mg lactose 140 mg 30 corn starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg 500 mg WO 2005/111005 33 PCT/EP2005/005079 The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to 5 produce tablets of suitable shape and size. B) Tablets per tablet 10 active substance 80 mg lactose 55 mg corn starch 190 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone 15 mg 15 sodium-carboxymethyl starch 23 mg magnesium stearate 2 mg 400 mg 20 The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size. 25 C) Ampoule solution active substance 50 mg sodium chloride 50 mg 30 water for inj. 5 ml The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are WO 2005/111005 34 PCT/EP2005/005079 then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance. D) Metering aerosol 5 Active substance 0.005 Sorbitan trioleate 0.1 TG134a : TG227 2:1 ad 100 10 The suspension is transferred into a conventional aerosol container with a metering valve. Preferably, 50 pil of suspension are delivered per spray. The active substance may also be metered in higher doses if desired (e.g. 0.02 % by weight). E) Solutions (in mg/I00ml) 15 Active substance 333.3 mg Benzalkonium chloride 10.0 mg EDTA 50.0 mg HCI (ln) ad pH 3.4 20 This solution may be prepared in the usual manner. F) Powder for inhalation 25 Active substance 12 ig Lactose monohydrate ad 25 mg The powder for inhalation is produced in the usual way by mixing the individual ingredients together.